척추신경추나의학회지 (The Journal of Churna Manual Medicine for Spine and Nerves)

  • 제13권2호
  • /
  • Pages.109-125
  • /
  • 2018
  • /
  • 1975-535X(pISSN)
  • /
  • 2982-6136(eISSN)
척추신경추나의학회 (Korean Society of Chuna manual Medicine for Spine and Nerves)
권호 표지
DOI QR코드

DOI QR Code

근골격계 질환에서 진단의학검사의 활용

Application of Clinical Laboratory Tests in Musculoskeletal Diseases

  • 하원배 (원광대학교 한의과대학 한방재활의학교실) ;
  • 금지혜 (원광대학교 한의과대학 한방재활의학교실) ;
  • 신선호 (우석대학교 한의과대학 한방재활의학교실) ;
  • 이정한 (원광대학교 한의과대학 한방재활의학교실)
  • Ha, Won-Bae (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Won-Kwang University) ;
  • Geum, Ji-Hye (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Won-Kwang University) ;
  • Shin, Seon-Ho (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Woo-Suk University) ;
  • Lee, Jung-Han (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Won-Kwang University)
  • 투고 : 2018.11.15
  • 심사 : 2018.12.11
  • 발행 : 2018.12.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives : It is difficult to make accurate diagnosis of musculoskeletal disease because of its multiple, subjective and non-specific symptoms. It is possible to reduce errors of differential diagnosis through detailed history taking and physical examination in parallel with laboratory tests based on clinical decision. Methods : Korean and foreign on-line databases(Pubmed, Cochran Library, NDSL, KISS and OASIS) were researched for articles discussing laboratory tests in musculoskeletal diseases. Results : Laboratory tests could be applied usefully for various musculoskeletal diseases, In this review, available laboratory components in these musculoskeletal diseases are summarized, and then significance and usefulness of disease-specific laboratory examination are described. Conclusions : When examining musculoskeletal patients, it needs to accurate differential diagnosis by full interview and physical examination, to select required tests by understanding laboratory tests thoroughly, and to judge the prognosis precisely.

키워드

참고문헌

  1. Woolf AD, Vos T, March L. How to measure the impact of musculoskeletal conditions. Best Pract Res Clin Rheumatol. 2010;24(6):723-32. https://doi.org/10.1016/j.berh.2010.11.002
  2. Bossuyt PM, Reitsma JB, Linnet K, Moons KG. Beyond diagnostic accuracy:the clinical utility of diagnostic tests. Clin Chem. 2012;58(12):1636-43. https://doi.org/10.1373/clinchem.2012.182576
  3. Kim HW. Interpreting Rheumatologic Lab Tests. Korean J Med. 2018;93(3):271-6. https://doi.org/10.3904/kjm.2018.93.3.271
  4. Jung KH. Diagnosis and Treatment of Arthritis. J Korean Neurol Assoc. 2017;35(4):25-30. https://doi.org/10.17340/jkna.2017.4.28
  5. Ahn JK. Clinical manifestations and diagnosis of systemic lupus erythematosus. Korean J Med. 2010;78(4):409-15.
  6. Kim WJ, Kim HJ. Multiple Sclerosis. J Korean Med Assoc. 2009;52(7):665-76. https://doi.org/10.5124/jkma.2009.52.7.665
  7. Jung JY, Suh CH. Update of Sjogren's Syndrome. Journal of Rheumatic Diseases. 2015;22(3):146-53. https://doi.org/10.4078/jrd.2015.22.3.146
  8. Seobuk hospital, Seoul metropolitan government. Standard Manual of Examination Task in Laboratory Medicine. 5th ed. Seoul. 2017:22-31.
  9. Park SK. An interpretation on abnormal finding of CBC. Korean J Med. 2010;78(5):531-9.
  10. Sox HC Jr, Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. Ann Intern Med. 1986;104(4):515-23. https://doi.org/10.7326/0003-4819-104-4-515
  11. Kim KH, Jeong MH, Shin JH, Joo SB, Kim W, Lee SU, Kim KH, Kim NH, Cho JH, Park JC, Na KJ, Ahn YK, Cho JG, Ahn BH, Park JC, Kang JC. The Role of Chronic Infection and Inflammation in Korean Patients with Coronary Artery Disease. Korean Circulation J. 2000;30(9):1107-16. https://doi.org/10.4070/kcj.2000.30.9.1107
  12. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100(1):96-102. https://doi.org/10.1161/01.CIR.100.1.96
  13. Emery P, Gabay C, Kraan M, Gomez-Reino J. Evidence based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int. 2007;27(9):793-806. https://doi.org/10.1007/s00296-007-0357-y
  14. Hanada M, Takahashi M, Furuhashi H, Koyama H, Matsuyama Y. Elevated erythrocyte sedimentation rate and high-sensitivity C-reactive protein in osteoarthritis of the knee: relationship with clinical findings and radiographic severity. Ann Clin Biochem. 2016;53(Pt 5):548-53. https://doi.org/10.1177/0004563215610142
  15. Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, Pepys MB. Low-level increases in serum Creactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum. 1997;40(4):723-7. https://doi.org/10.1002/art.1780400419
  16. Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine. 2007;74(3):249-53. https://doi.org/10.1016/j.jbspin.2006.07.005
  17. Keenan RT, Swearingen CJ, Yazici Y. Erythrocyte sedimentation rate and Creactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol. 2008;26(5):814-9.
  18. Wolfe F. The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. J Rheumatol. 1997;24(8):1486-8.
  19. Visser H. Early diagnosis of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2005;19(1):55-72. https://doi.org/10.1016/j.berh.2004.08.005
  20. Park SH. New diagnostic method of rheumatoid arthritis. Korean J Med. 2009;76(1):7-11.
  21. Kim KH. Laboratory Evaluation of Autoimmune Diseases. Medical Postgraduates. 2011;39(1):7-15.
  22. Lopez-Longo FJ, Sanchez-Ramon S, Carreno L. The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factor? Drug News Perspect. 2009;22(9):543-8. https://doi.org/10.1358/dnp.2009.22.9.1437962
  23. Westgeest AA, Boerbooms AM, Jongmans M, Vandenbroucke JP, Vierwinden G, van de Putte LB. Antiperinuclear factor: indicator of more severe disease in seronegative rheumatoid arthritis. J Rheumatol. 1987;14(5):893-7.
  24. Satoh M, Vazquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody test in systemic rheumatic diseases. Mod Rheumatol. 2009;19(3):219-28. https://doi.org/10.3109/s10165-009-0155-3
  25. Kwok SK. Review of Sjogren's Syndrome for Primary Physicians. Korean J Med. 2015;89(3):291-4. https://doi.org/10.3904/kjm.2015.89.3.291
  26. Flechsig A, Rose T, Barkhudarova F, Strauss R, Klotsche J, Dahnrich C, Schlumberger W, Enghard P, Burmester GR, Hiepe F, Biesen R. What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with antidsDNA antibodies and C3. Clin Exp Rheumatol. 2017;35(4):598-606.
  27. Lee SH. The New Classification Criteria of Systemic Lupus Erythematosus. Korean J Med. 2014;87(4):389-94. https://doi.org/10.3904/kjm.2014.87.4.389
  28. Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjogren's Syndrome. Rheum Dis Clin North Am. 2016;42(3):419-34. https://doi.org/10.1016/j.rdc.2016.03.002
  29. Ippolito A, Wallace DJ, Gladman D, Fortin PR, Urowitz M, Werth V, Costner M, Gordon C, Alarcon GS, Ramsey-Goldman R, Maddison P, Clarke A, Bernatsky S, Manzi S, Bae SC, Merrill JT, Ginzler E, Hanly JG, Nived O, Sturfelt G, Sanchez-Guerrero J, Bruce I, Aranow C, Isenberg D, Zoma A, Magder LS, Buyon J, Kalunian K, Dooley MA, Steinsson K, van Vollenhoven RF, Stoll T, Weisman M, Petri M. Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. Lupus. 2011;20(3):250-5. https://doi.org/10.1177/0961203310385738
  30. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity. 2005;38(1):47-54. https://doi.org/10.1080/08916930400022715
  31. Theander E, Jonsson R, Sjostrom B, Brokstad K, Olsson P, Henriksson G. Prediction of Sjogren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol. 2015;67(9):2427-36. https://doi.org/10.1002/art.39214
  32. Guldner HH, Szostecki C, Vosberg HP, Lakomek HJ, Penner E, Bautz FA. Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I. Chromosoma. 1986;94(2):132-8. https://doi.org/10.1007/BF00286991
  33. de Rooij DJ, Van de Putte LB, Habets WJ, Van Venrooij WJ. Marker antibodies in scleroderma and polymyositis:clinical associations. Clin Rheumatol. 1989;8(2):231-7. https://doi.org/10.1007/BF02030079
  34. Spath M, Schroder M, Schlotter-Weigel B, Walter MC, Hautmann H, Leinsinger G. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol 2004;251:859-64.
  35. Chen B, Li J, He C, Li D, Tong W, Zou Y, Xu W. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis. Mol Med Rep. 2017;15(4):1943-51. https://doi.org/10.3892/mmr.2017.6248
  36. Kim SY. Counsel for diagnosis and treatment of rheumatism. Korean J Med. 2000;58(1):3-11.
  37. Hong YH, Lee CK. Treatment of gout. Korean J Med.. 2005;69(4):459-62.
  38. Kim KA. Understanding and application of liver function tests. Korean J Med. 2009;76(2):163-8.
  39. David HJ. Diagnosis and management of inflammatory muscle disease. J Neurol Neurosurg Psychiatry. 2003;74(Suppl II):ii25-ii31. https://doi.org/10.1136/jnnp.74.1.25
  40. Volochayev, Csako G, Wesley R, Rider LG, Miller FW. Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. Open Rheumatol J. 2012;6:54-63. https://doi.org/10.2174/1874312901206010054
  41. Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus eythematosus: an update. Ann Rheum Dis. 2014;73(9):1601-6. https://doi.org/10.1136/annrheumdis-2014-205287
  42. Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, Wu H, Yu CY, Hebert LA, Rovin BH. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus. 2010;19(11):1272-80. https://doi.org/10.1177/0961203310371154
  43. Lee JH, Choi YC. Rhabdomyolysis. Korean J Neuromuscul Disord. 2016;8(1):22-7.
  44. Kim MJ. Clincal Study of Nontraumatic Rhabdomyolysis. Korean J Med. 2004;67(5):459-60.
  45. Kang HC. Interpretation of Thyroid Function Test. Korean J Med. 2010;78(Suppl I):S18-25.
  46. Chung HW, Kang BM, Kim MR, Yoon BK, Lee BS, Choi HC, Park HM, Kim JG. The Infl uence of Thyroid Function on Bone Mineral Density in Korean Postmenopausal Women. J Korean Soc Menopause. 2012;18:36-42.
  47. Lee SH, Lee DR, Lee DJ, Kim KM, Park SB, Kim BT. Interpretation of Tests for Autoimmune Disease. Korean J Fam Pract. 2012;2:221-32.
  48. Kwon SH, Han DC. Diagnosis and screening of chronic kidney disease. Korean J Med. 2009;76(5):515-20.
  49. Seligman VA, Lum RF, Olson JL, Li H, Criswell LA. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med. 2002;112:726-9. https://doi.org/10.1016/S0002-9343(02)01118-X
  50. Chan TM. Histological reclassification of lupus nephritis. Curr Opin Nephrol Hypertens 2005;14:561-6, https://doi.org/10.1097/01.mnh.0000168934.18399.97
  51. Felson DT. The epidemiology of knee osteoarthritis: Results from the framingham osteoarthritis study. Semin Arthritis Rheum. 1990;(3 Suppl 1):42-50.
  52. Lee KH, Lee SK. Pathophysiology of Gout. Korean J Med. 2011;80(3):251-4.
  53. Colavite PM, Sartori A. Septic arthritis: immunopathogenesis, experimental models and therapy. J Venom Anim Toxins Incl Trop Dis. 2014;20:19. https://doi.org/10.1186/1678-9199-20-19
  54. Calmbach WL, Hutchens M. Evaluation of patients presenting with knee pain: Part I. History, physical examination, radiographs, and laboratory tests. Am Fam Physician. 2003;68(5):907-12.
  55. Brunham RC, Gottlieb SL, Paavonen J. Pelvic Inflammatory Disease. N Engl J Med. 2015;372(21):2039-48. https://doi.org/10.1056/NEJMra1411426
  56. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. https://doi.org/10.1002/art.34473
  57. Lee SW. Laboratory findings and renal pathology in systemic lupus erythematosus. Korean J Med. 2010;78(4):416-24.
  58. Ramos-Casals M, Nardi N, Brito-Zeron P, Aguilo S, Gil V, Delgado G, Bove A, Font J. Atypical autoantibodies in patients with primary Sjogren syndrome: clinical characteristics and followup of 82 cases. Semin Arthritis Rheum. 2006;35(5):312-21. https://doi.org/10.1016/j.semarthrit.2005.12.004
  59. Chen B, Li J, He C, Li D, Tong W, Zou Y, Xu W. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis. Mol Med Rep. 2017;15(4):1943-51. https://doi.org/10.3892/mmr.2017.6248
  60. Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT. The clinical usefulness of ESR, CRP, and disease duration in ankylosing spondylitis: the product of these acute-phase reactants and disease duration is associated with patient's poor physical mobility. Rheumatol Int. 2015;35(7):1263-7. https://doi.org/10.1007/s00296-015-3214-4
  61. Oh SH, Kim SM, Sunwoo IN, Lee DH, Kim TS, Kim SH, Choi YC. The Clinical and Pathological Characteristics of Polymyositis Using ENMC Diagnostic Criteria. J Rheum Dis. 2008;15(4):296-305.
  62. Lee SW, Jung SY, Park MC, Park YB, Lee SK. Malignancies in Korean patients with inflammatory myopathy. Yonsei Med J. 2006;47:519-23. https://doi.org/10.3349/ymj.2006.47.4.519
  63. Kim HS. Updated Classification Criteria for Systemic Sclerosis: the Concept of Early Diagnosis. Korean J Med. 2014;87(4):395-400. https://doi.org/10.3904/kjm.2014.87.4.395
  64. Adnan ZA. Diagnosis and treatment of scleroderma. Acta Med Indones. 2008;40(2):109-12.
  65. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-95. https://doi.org/10.1001/jama.285.6.785
  66. Kim BT, Lee SH. Diagnostic Approach to Osteoporosis: Interpretation of Bone Density Measurement. Korean J Fam Pract. 2013;3:6-15.
  67. Yoon JK, Kye SS, Lee JH, Lee JM, Seo JM, Park JH, Cho YD. Association between Alkaline Phosphatase with Bone Mineral Density in 50s Healthy Korean Men. Korean J Fam Pract. 2015;5(3):247-52.
  68. Park JY, Choi MY, Lee SH, Choi YH, Park YK. The Association between Bone Mineral Density, Bone Turnover Markers, and Nutrient Intake in Pre-and Postmenopausal Women. Korean J Nutr. 2011;44(1):29-40. https://doi.org/10.4163/kjn.2011.44.1.29
  69. Kim HS, Choi YH, Park KC, Park YS. Osteoporotic Spinal Compression Fracture and Degree of Vitamin D Deficiency. J Korean Fract Soc. 2013;26(1):27-31. https://doi.org/10.12671/jkfs.2013.26.1.27
  70. Lee SS. Newer Diagnostic Criteria of Fibromyalgia and Its Clinical Implications. J Rheum Dis. 2011; 18(3):153-60. https://doi.org/10.4078/jrd.2011.18.3.153
  71. Lee SS. Diagnosis and Treatment of Fibromyalgia Syndrome. Korean J Med. 2013;84(5):650-8. https://doi.org/10.3904/kjm.2013.84.5.650